Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Veracyte Inc (VCYT) Jumps On New Aetna Inc. (AET) Deal: Is It A Good Stock To Buy?

Page 1 of 2

Veracyte Inc (NASDAQ:VCYT) shares climbed as high as $12.13 per share on Friday as the firm announced that it has signed a deal with Aetna Inc. (NYSE:AET) which will come into effect on July 1 to become a part of the latter’s laboratory network. Shares ended the day up by nearly 7%. Veracyte Inc is a molecular diagnostics firm which specializes in the molecular cytology field. Its flagship product is the Afirma Thyroid FNA analysis, which is a test that is part of a thyroid cancer diagnosis when benign thyroid nodules among those deemed unclassified by cytopathology need to be identified. BTIG Research also reaffirmed its rating of “Buy” on the stock in a note on Thursday. BTIG has a price target of $13 on the stock. The company’s shares slid 2.95% on Thursday to a closing price of $11.18 per share. Year-to-date, the stock has increased 25.53% in value. For the past one-year period, however, the company’s shares have declined by 31.71%.

Biotech Biochemical Stocks 3

The renewed positivity of the market today mirrors that of hedge fund sentiment on the stock, in terms of number of hedge funds with long positions in the company. At the end of the first quarter, a total of seven of the hedge funds tracked by Insider Monkey were bullish in this stock, a change of 17% from the fourth quarter. However, bearish sentiment can be seen in the total value of holdings going down by 37.63% to about $13 million during the first quarter from about $20.84 million at the end of the previous quarter. Even factoring in the share price decline of 24.64% in the first quarter, there was a small pullback in the stock from top money managers.

We pay attention to hedge funds’ moves because our research have shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular stock picks in real time since the end of August 2012. These stocks returned 142% since then and outperformed the S&P 500 Index by 84 percentage points (see more details here). That’s why we believe it is important to pay attention to hedge fund sentiment. Plus, we also don’t like paying huge fees.

Insider Monkey additionally tracks insider sentiment in the form of share sales or share purchases. However, there were no recorded sales or purchases of Veracyte Inc shares by insiders in the first half of the year. Taking this into account, let us examine how hedge funds have been trading shares of the company recently.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!